Admissions:
Delistings:
Intelligent Ultrasound Group (IUG.L) delisted from AIM.
Potential** Initial Public Offerings:
6 February: GlobalData (DATA.L) has announced an intention to move to the Main Market from AIM. An update on the timing and process to seek Admission will be provided in due course.
6 February: Creightons (CRL.L) has announced an intention to move to AIM from the Main Market. Timing is subject to various approvals, but for 31 March.
Corero Network Security 17.50p £89.63m (CNS.L)
The Distributed Denial of Service (DDoS) protection specialists yesterday reported a new contract and a partnership deal in Latin America. The new contract is with a Brazilian telecommunications provider to implement Corero's SmartWall ONE solution. Corero is also expanding into Peru through a new partnership with A51 Technology, a firm with over 20 years of experience. This partnership will enable Corero to target new opportunities across Peru in cybersecurity solutions. The continued investment in regional alliances is a key element of its reinvigorated go-to-market strategy.
Duke Capital Limited 30.50p £154.22m (DUKE.L)
The provider of hybrid capital solutions for SME businesses in Europe and North America reports a follow-on investment of £1.9m into its existing capital partner, BPVA (Ireland), to enable it to complete a further acquisition. The BPVA Group is an investment holding company established in 2018 to execute a buy and build strategy of synergistic companies within the Irish/UK Resourcing and Talent sector. Since Duke's initial investment, BPVA has made five major acquisitions along with five smaller bolt-on deals and is now made up of ten businesses, as it seeks to provide high-quality consultancy and recruitment services across Europe.
Firering Strategic Minerals 5.30p £9.77m (FRG.L)
The emerging quicklime production and critical mineral exploration Company is firing its first gasifier and Kiln 1 at its Limeco quicklime project to commence quicklime production. This is a key step towards achieving full-scale operations across all eight kilns by the end of 2025. Once at steady-state production, (100 tonnes of quicklime per kiln per day) Limeco will produce over 200,000 tonnes annually, establishing itself as one of Zambia's largest quicklime producers and an important supplier to the growing copper industry in the Central African Copperbelt.
Helium One 0.95p £56.02m (HE1.L)
The helium explorer updates on the Blue Star Helium (ASX:BNL) announcement regarding the Galactica Project. It has spudded the 3054-helium development well and is currently preparing to drill. The shallow conductor section has been set, and the Blowout Preventor is now being installed and tested ahead of drilling out the intermediate hole section. When Target Depth is reached, wireline logging will then be undertaken, followed by flow and pressure readings at the wellhead. This data will be used to estimate the potential of the well based on the production model. Helium One operates mainly in Tanzania, but with a 50% working interest in the Galactica-Pegasus helium development project in Colorado, US.
Inspiration Healthcare Group 23.5p £21.1m (IHC.L)
The global medical technology Company specialist neonatal intensive care medical devices yesterday updated on Trading for Y/E January 2025. After a strong H2, revenue for the full year is expected at £38.3m, which is slightly ahead of last year’s £37.6m. The new CEO expects to return to EBITDA positive after a cost reduction programme was implemented during the second half delivering annualised savings of £1.25m. Encouragingly, prior to the year end, the Company won its largest single contract of $6m for ventilators plus associated accessories and consumables from a trusted global humanitarian aid organisation. Delivery of this contract is anticipated to be in the first half of this financial year and is expected to contribute to increased profitability in the current year.
Ondine Biomedical Inc. 11.5p £50.8m (OBI.L)
The Canadian life sciences Company and leader in light-activated antimicrobial therapies reports that its innovative light-activated antimicrobial treatment has the potential to become the first FDA-approved nasal decolonisation treatment for the prevention of surgical site infections. The treatment is presently undergoing a pivotal phase 3 trial (LANTERN) in US hospitals. It has already successfully treated over 200,000 patients in Canada and the UK, and both patients and clinicians have embraced the added protection that Steriwave provides against infection risks. This nasal decolonisation would apply to more than 35m major surgical procedures in the US annually.
OptiBiotix Health 16p £15.7m (OPTI.L)
The life sciences business developing compounds to tackle obesity, high cholesterol, diabetes, and skincare, yesterday launched FeelFull, in the US. It contains SlimBiome, which is science-backed and clinically supported to impact on gut health. It is distributed by Daily Nouri, a known US brand selling products online and in stores of some of the largest retailers in the US such as Walmart and Albertsons. The ‘On-Pack' health claims are important in differentiating products in the weight management market and are an area of high consumer interest since the launch of the appetite reducing anti-obesity drugs. This follows launches in India, China, large parts of Asia and now the US. The CEO states that while this global approach is taking longer to establish, it has the potential to create multiple revenue streams to build a substantial business.
Pharos Energy 23.6p £97.3m (PHAR.L)
The independent energy Company with assets in Vietnam and Egypt has entered into a non-binding Memorandum of Understanding (MOU) with the Egyptian General Petroleum Corporation in relation to the merger of the El Fayum and North Beni Suef Concession Agreements. The consolidated Concession Agreement is expected to unlock significant value in the Western Desert by improving fiscal terms, extending the term of the concessions, and committing the Contractor parties to additional work programmes aimed at increasing production from the areas. The CEO stated the MOU was key to further organic growth from its Egyptian portfolio and should generate significant value for shareholders and aims to complete negotiations as soon as possible.
Sovereign Metals Limited 41p £239m (SVML.L)
The UK-based mining Company specialising in exploration and development of mineral resources, notably graphite and other industrial minerals, reports on its test work. A comprehensive program was completed by ProGraphite GmbH and Dorfner Anzaplan in Germany. This demonstrated that Kasiya graphite concentrate contains very low sulphur levels and the absence of other impurities of concern, providing a competitive advantage over other sources of graphite supply. The testing highlights the premium quality of Kasiya graphite concentrate providing a strong foundation for sales and marketing discussions. It confirms that the graphite product also meets or exceeds the key chemical and physical properties required to sell into the refractory market. The refractories market is the second largest end-user of natural graphite and requires larger, coarser graphite flakes with specific chemical and physical properties.
Tracsis 360p £109.4m (TRCS.L)
The transport technology provider has signed a multi-year contract with Rail Settlement Plan, a division of Rail Delivery Group, to implement the core Tap Converter system that will power pay-as-you-go (PAYG) travel in urban areas across National Rail, processing all related transactions and fare calculations. It is a major contract win through a competitive bid process, to provide the central smart ticketing technology platform. The CEO says that the contract represents a major milestone in its smart ticketing technology journey, with the potential to grow into a valuable, long-term partnership over time
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
